Downregulation of microRNA-128b, due to loss of heterozygosity of 3p22 in lung tumor specimens, was associated to increased epidermal growth factor receptor (EGFR) expression with a consequent survival benefit in patients treated with gefitinib, a EGFR-tyrosine kinase inhibitor drug commonly used in advanced NSCLC management [13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.